Is This Pharmaceutical Giant a Winning Tariff-Proof Stock to Buy for 2026? [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
NVS maintains a 100% “Buy” technical opinion from Barchart. Novartis has benefitted in recent days from its CEO's comments that the company will have essentially limited tariff exposure by mid-2026. Valued at $310.8 billion, Novartis (NVS) is a pharmaceutical giant with a portfolio that spans oncology, immunology, neuroscience, and more. Some of its well-known products include Entresto, Cosentyx, Kesimpta, and Kisqali. I found today's Chart of the Day by using Barchart's powerful screening functions to sort for stocks with the highest technical buy signals; superior current momentum in both strength and direction; and a Trend Seeker “buy” signal. I then used Barchart's Flipcharts feature to review the charts for consistent price appreciation. NVS checks those boxes. Since the Trend Seeker issued a new “Buy” on Dec. 2, shares are up 11.23%. Michael Burry Is Probably Wrong About Timing - But Right About What Comes Next Earnings, Tariffs and Other Key Things to Watch this Week
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Even Near an All-Time High, This Dividend ETF Looks Extremely Cheap [Yahoo! Finance]Yahoo! Finance
- Why Analysts Are Closely Watching Novartis AG (NVS) [Yahoo! Finance]Yahoo! Finance
- NFL Greats and Novartis Tackle Prostate Cancer Myths at Super Bowl LX: "Relax, It's a Blood Test"PR Newswire
- Breakthrough Therapy Status For Ianalumab Could Be A Game Changer For Novartis (SWX:NOVN) [Yahoo! Finance]Yahoo! Finance
- Eaton Vance Worldwide Health Sciences Fund Reduces Stake in Novo Nordisk AS by 49.25% [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 10/28/25 - Miss
NVS
Sec Filings
- 1/16/26 - Form S-8
- 1/16/26 - Form S-8
- 1/16/26 - Form S-8
- NVS's page on the SEC website